Magnesium Taurate

• CAS: 334824-43-0
• Catalog Number: ALC-FP-334824430
• Category: Featured Products
• Appearance: White powder
• Content: Magnesium (on dried basis)≥ 8.0%; Pb≤ 3ppm; As≤ 1ppm; Cd≤ 1ppm; Hg≤ 0.1ppm
• D50: 90% passing 60 mesh
• E. Coli: Negative
• Drying Loss: ≤ 10.0%
• Mold And Yeast: ≤ 100 cfu/g
• pH: 5.0-7.0
• Salmonella: Negative
• Sample Lot No.: A24D05211
• Total Plate Count: ≤ 1000 cfu/g

Case Study

Magnesium Taurate for Attenuating Cadmium-Induced Hypertension and Cardiotoxicity

Shrivastava P, et al. Journal of Traditional and Complementary Medicine, 2019, 9(2), 119-123.

Magnesium taurate was experimentally applied as an oral therapeutic agent to mitigate cadmium chloride-induced hypertension and myocardial injury in Sprague Dawley rats. Hypertension was first established by intraperitoneal CdCl₂ administration (0.5 mg/kg/day for four weeks). Magnesium taurate (2 or 4 mg/kg/day, p.o.) was introduced after two weeks of CdCl₂ exposure and administered concurrently for the remaining two weeks to assess its intervention capability. Throughout the study, blood pressure was monitored biweekly using a non-invasive system, and myocardial oxidative markers-including GPx, SOD, catalase, GSH, and MDA-were quantified at termination. Histopathological evaluation confirmed reduced myocardial degeneration, demonstrating the product's experimental effectiveness in restoring cardiovascular function under toxic stress.

Magnesium Taurate for Delaying Galactose-Induced Cataract Formation

Agarwal R, et al. Experimental Eye Research, 2013, 110, 35-43.

Magnesium taurate was experimentally evaluated for its anticataract efficacy using both in vivo and in vitro galactose-induced cataract models. In rats fed a 30% galactose diet, magnesium taurate was administered either orally or topically, followed by weekly slit-lamp assessments over 21 days. Isolated lenses were analyzed for Ca²⁺/Mg²⁺ ratios and antioxidant markers (GSH, catalase, SOD) via ELISA. Parallel in vitro experiments involved incubating normal rat lenses in galactose-supplemented DMEM, with one group receiving magnesium taurate supplementation. Across both models, magnesium taurate treatment markedly reduced lens opacity, normalized Ca²⁺/Mg²⁺ homeostasis, and restored antioxidant activity, demonstrating its experimental effectiveness in delaying cataract onset and progression.

Magnesium Taurate for Preventing Hypertensive Cadmium-Induced Cataractogenesis

Choudhary R, et al. Biomedicine & Pharmacotherapy, 2016, 84, 836-844.

Magnesium taurate was experimentally evaluated for its protective efficacy against cadmium chloride-induced hypertension-associated cataractogenesis in Sprague-Dawley rats. The model involved six weeks of CdCl₂ administration (0.5 mg/kg/day, i.p.), during which magnesium taurate was orally co-administered at 3 or 6 mg/kg/day. This experimental application demonstrated that MgT restored lenticular antioxidant systems (CAT, SOD, GPx, GSH), normalized ionic balance (Na⁺, K⁺, Ca²⁺), and enhanced Ca²⁺-ATPase and Na⁺/K⁺-ATPase activities in isolated lenses. Biweekly assessments of blood pressure, heart rate, and ophthalmoscopic imaging confirmed that MgT delayed cataract progression. The study highlights MgT's capacity to counteract oxidative stress, restore ATPase function, and mitigate cataract formation under hypertensive and cadmium-induced stress conditions.